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Metabolites in the kynurenine pathway, generated
by tryptophan degradation, are thought to play an
important role in neurodegenerative disorders,
including Alzheimer’s and Huntington’s diseases.
In these disorders, glutamate receptor-mediated
excitotoxicity and free radical formation have been
correlated with decreased levels of the neuroprotec-
tive metabolite kynurenic acid. Here, we describe the
synthesis and characterization of JM6, a small-
molecule prodrug inhibitor of kynurenine 3-monoox-
ygenase (KMO). Chronic oral administration of JM6
inhibits KMO in the blood, increasing kynurenic
acid levels and reducing extracellular glutamate
in the brain. In a transgenic mouse model of
Alzheimer’s disease, JM6 prevents spatial memory
deficits, anxiety-related behavior, and synaptic
loss. JM6 also extends life span, prevents synaptic
loss, and decreases microglial activation in a mouse
model of Huntington’s disease. These findings
support a critical link between tryptophan metabo-
lism in the blood and neurodegeneration, and they
provide a foundation for treatment of neurodegener-
ative diseases.
INTRODUCTION
Alzheimer’s disease (AD) is the most common neurological
disease in humans, and Huntington’s disease (HD) is among
the most common inherited neurodegenerative diseases. Themolecular mechanisms of neurodegeneration in these lethal
conditions are unclear, and currently no disease-modifying
therapies exist.
Experiments in rodents suggest a link between metabolites of
the kynurenine pathway (KP), the major route of tryptophan
degradation in mammals (Figure 1), and excitotoxicity, a mecha-
nism of neuronal dysfunction and cell death characterized by
excessive stimulation of glutamate receptors, pathological ele-
vation of intracellular free calcium, and mitochondrial damage.
Many neuropathological features and chemical impairments in
HD can be duplicated in experimental animals by an intrastriatal
injection of the KP metabolite quinolinic acid (QUIN) (Schwarcz
et al., 1983). These findings led to the hypothesis that QUIN,
a selective N-methyl-D-aspartate (NMDA) receptor agonist
found in mammalian brain, contributes to the pathophysiology
of HD.
Excitotoxicity and the KP have also been implicated in the
pathogenesis of AD. Injection of QUIN into the nucleus basalis
of rats destroys cholinergic neurons projecting to the cortex
and causes significant decreases in cortical choline acetyltrans-
ferase, acetylcholinesterase, high-affinity choline uptake, and
3H-acetylcholine release, which parallel changes observed in
AD brains (Boegman et al., 1985). Continuous intraventricular
infusion of QUIN also causes memory deficits that resemble
those in AD patients (Misztal et al., 1996).
Kynurenic acid (KYNA), formed in a side arm of the KP (Fig-
ure 1), is also thought to modulate excitotoxicity and neurode-
generation. Upon intracerebral application, KYNA blocks
QUIN-induced neurodegeneration (Foster et al., 1984), and
KYNA is neuroprotective in clinically relevant animal models
of brain ischemia (Andine´ et al., 1988; Nozaki and Beal,
1992). Notably, genetic reduction in KYNA formation enhances
vulnerability to an excitotoxic insult (Sapko et al., 2006). AtCell 145, 863–874, June 10, 2011 ª2011 Elsevier Inc. 863
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Figure 1. The Kynurenine Pathway of Trypto-
phan Degradation in Mammals
KMO functions at a key branching point in the ky-
nurenine pathway (KP). Inhibition of KMO causes
the accumulation of its substrate kynurenine and
a shunt in the KP, leading to increased production
of the neuroprotective molecule KYNA.supraphysiological concentrations, KYNA is a broad-spectrum
antagonist of ionotropic excitatory amino acid receptors (Perkins
and Stone, 1982). At endogenous brain concentrations, KYNA
competitively blocks the glycine coagonist site of the NMDA
receptor (Kessler et al., 1989) and noncompetitively inhibits the
a7 nicotinic acetylcholine receptor (Hilmas et al., 2001). Even
modest increases in brain KYNA reduce extracellular glutamate
levels in brain by inhibiting presynaptic a7 nicotinic receptors
(Carpenedo et al., 2001).
The neostriatal and neocortical levels of the KP metabolites
3-hydroxykynurenine (3-HK), a free radical generator that medi-864 Cell 145, 863–874, June 10, 2011 ª2011 Elsevier Inc.ates neuronal cell death (Okuda et al.,
1996), and QUIN are significantly elevated
in early pathological-grade HD brains
(Guidetti et al., 2004), whereas KYNA
levels are decreased (Beal et al., 1992).
Moreover, cerebral 3-HK and QUIN
concentrations are also increased in
mouse models of HD (Guidetti et al.,
2006). In the serum of HD patients, trypto-
phan levels are reduced, and the kynureni-
ne:tryptophan ratio is elevated, coinciding
with increased production of proinflam-
matory cytokines and chemokines (Stoy
et al., 2005). Similar findings have been
described in AD patients (Gulaj et al.,
2010; Heyes et al., 1992a). Thus, analo-
gous changes in KP metabolite levels are
found in the central nervous system
(CNS) and in the periphery in HD and AD,
and it is widely hypothesized that these
events are early contributors to the patho-
physiology of both diseases.
Kynurenine 3-monooxygenase (KMO)
functions at a key branching point of the
KP (Figure 1), whereby KMO inhibition
shunts KP metabolism toward enhanced
KYNA production and may therefore
reduce neuronal vulnerability. Indeed, the
most widely used KMO inhibitor, Ro
61-8048 (Ro¨ver et al., 1997), is beneficial
in rodent models of brain ischemia (Moroni
et al., 1999), cerebral malaria (Clark et al.,
2005), and trypanosomiasis (Rodgers
et al., 2009) and in a primate model of
Levodopa-induced dyskinesias (Gre´goire
et al., 2008). However, we found that
Ro 61-8048 is metabolically unstable
(data not shown) and therefore developed‘‘slow-release’’ prodrugs of Ro 61-8048 with improved meta-
bolic stability that could be tested in mouse models of chronic
neurodegenerative diseases.
Here, we describe the effects of 2-(3,4-dimethoxybenzene-
sulfonylamino)-4-(3-nitrophenyl)-5-(piperidin-1-yl)methylthiazole
(JM6), an orally bioavailable prodrug of Ro 61-8048 (Figure 2A),
on behavioral and neuropathological deficits in transgenic
mouse models of AD and HD. Treatment with JM6 prevented
synaptic loss and behavioral deficits in these models by
increasing extracellular brain levels of the neuroprotective KP
metabolite KYNA and decreasing extracellular glutamate. We
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Figure 2. JM6, a Prodrug Inhibitor of KMO,
Increases Brain KYNA by Blocking KMO in
the Blood
(A) Chemical synthesis of JM6. JM6 is a prodrug of
the KMO inhibitor Ro 61-8048.
(B) Hypothetical mechanism for the acid-induced
release of Ro 61-8048 from JM6.
(C and D) JM6 (C) and Ro 61-8048 released from
JM6 (D) accumulate at high levels in plasma, but
not in brain or other tissues, 5 hr after JM6
administration (300 mg/kg p.o.) in mice. Absolute
concentrations of JM6 were 40 mM (plasma),
119 nM (brain), 1.6 mM (muscle), and 5 mM (liver)
(n = 5). Absolute concentrations of Ro 61-8048
were 7 mM (plasma), 18 nM (brain), 149 nM
(muscle), and 132 nM (liver) (n = 5).
(E) Extracellular KYNA levels in the striatum of
rats measured by microdialysis following acute
JM6 treatment (100 mg/kg, p.o.; arrow). In addi-
tion, in one group of animals, the KAT II inhibitor
ESBA (1 mM) was applied by reverse dialysis for
the first 2 hr and prevented the JM6-induced
increase in KYNA levels (p < 0.001, repeated
measures two-way ANOVA; n = 5 per treatment
group).
(F) In the same rats, serum KYNA levels rose
equally over time in the two groups, i.e., intrace-
rebral ESBA administration did not influence
circulating KYNA levels in JM6-treated rats.
(G) Extracellular KYNA and glutamate were
determined by in vivo microdialysis in the
prefrontal cortex of rats treated for 7 days with
JM6 (100 mg/kg/day p.o.). Baseline values for
control rats were 2.5 ± 0.1 nM (KYNA) and 2.0 ±
0.2 mM (glutamate).
(H) Extracellular KYNA correlates negatively with
extracellular glutamate in these animals.
*p < 0.05; **p < 0.01 (t test). n = 6 per group. Values
in (C)–(G) are means ± SEM.found, unexpectedly, that JM6 andRo 61-8048 do not effectively
cross the blood-brain barrier, indicating that peripheral inhibition
of KMO is sufficient to confer neuroprotection through the
accumulation and active transport of the tryptophan metabolite
kynurenine into the brain from the periphery and subsequent
conversion to KYNA.
RESULTS
JM6 Increases Brain KYNA by Inhibiting KMO in Blood
We hypothesized that JM6 acts as a prodrug and would be
metabolized under acidic conditions in the gut to slowly releaseCell 145, 863–8Ro 61-8048 and thereby provide long-
lasting inhibition of KMO (Figures 2A
and 2B). To investigate the pharmacoki-
netic properties of JM6, we treated
wild-type (WT) mice with a single high
dose of JM6 (300 mg/kg p.o.) and
measured JM6 and Ro 61-8048 in
plasma, brain, muscle, and liver byliquid chromatography/mass spectrometry (LC/MS) 5 hr after
administration. JM6 accumulated in plasma at a high concentra-
tion (39.1 ± 13.2 mM), but only very low levels were detected in
the brain (119 ± 46 nM, or 0.003% of plasma levels) (Figure 2C).
The brain concentration of JM6 was well below the IC50 of this
compound for KMO (4 mM). Ro 61-8048 released from JM6
was also present at a high concentration (7.2 ± 0.8 mM) in plasma
but only at very low levels in the brain (18 ± 5 nM, or 0.002% of
plasma levels) (Figure 2D), i.e., also below its IC50 for KMO
(37 nM). Muscle and liver levels of JM6 and Ro 61-8048 after
acute dosing were also negligible. Direct administration of Ro
61-8048 (100 mg/kg p.o.) to WT mice also resulted in high74, June 10, 2011 ª2011 Elsevier Inc. 865
plasma levels but negligible brain exposure (data not shown).
Thus, JM6 is a prodrug of Ro 61-8048 in vivo that accumulates
predominantly in blood, but neither JM6 itself nor Ro 61-8048
released from JM6 penetrates the blood-brain barrier to any
significant extent.
Previous studies have shown that treatment of rodents with
Ro 61-8048 raises brain KYNA levels (Ro¨ver et al., 1997).
However, neither Ro 61-8048 (Figure 2D) nor KYNA (Fukui
et al., 1991) crosses the blood-brain barrier effectively. In
contrast, the substrate of KMO, kynurenine, is actively trans-
ported into the CNS by a neutral amino acid transporter and is
then rapidly converted to KYNA (Fukui et al., 1991). We therefore
hypothesized that the effect of Ro 61-8048 on brain KYNA levels
is secondary to inhibition of KMO in blood cells, followed by an
increase in circulating kynurenine levels, active transport of
kynurenine into the CNS, and astrocyte-mediated conversion
to KYNA.
To test whether systemic administration of JM6 influences
the KP in the brain, we performed in vivo microdialysis in the
striatum of awake, behaving rats to measure extracellular
KYNA as a pharmacodynamic readout of KMO inhibition in
the periphery. A single injection of JM6 (100 mg/kg p.o.)
increased KYNA levels in both brain (Figure 2E) and serum (Fig-
ure 2F), peaking at 180% and 344%, respectively, of baseline
levels. JM6 and Ro 61-8048 were detected only at extremely
low levels (<10 nM) in brain dialysate (data not shown), similar
to results obtained in pharmacokinetic studies (Figures 2C
and 2D). In contrast, plasma levels of Ro 61-8048 released
from JM6 coincided temporally and were correlated with an
increase in KYNA levels in both plasma and brain (data not
shown).
In one set of animals, we examined whether the elevation in
brain KYNA levels seen after oral administration of JM6 was
generated by kynurenine aminotransferase II (KAT II), the
enzyme that is predominantly responsible for KYNA production
in the rat brain (Guidetti et al., 2007). To this end, rats were
treated with JM6 (100 mg/kg p.o.), and a small molecule KAT II
inhibitor ([S]-[4-ethylsulfonyl]benzoylalanine hydrochloride;
ESBA; Pellicciari et al., 2006) (1 mM) was applied locally for
2 hr by reverse microdialysis. JM6-induced increases in brain
KYNA were prevented completely by treatment with ESBA,
and KYNA levels in serum were unaffected (Figures 2E and
2F). These results provide unequivocal evidence that increased
brain KYNA levels in rats treated with JM6 are due to de novo
production of KYNA within the CNS.
Similar increases in extracellular KYNA in the brain were seen
in rats treated chronically with JM6 for 7 days (100 mg/kg/day
p.o.), and this effect was accompanied by a significant reduction
in extracellular glutamate levels (Figure 2G), consistent with
a previous microdialysis study in the striatum of rats treated
acutely with Ro 61-8048 (4–40 mg/kg i.p.) (Moroni et al., 2005).
Importantly, a strong negative correlation between extracellular
KYNA and glutamate was observed in rats after treatment with
JM6 (Figure 2H). These findings confirm that JM6 is a prodrug
that leads to slow release of Ro 61-8048 in blood, increases brain
levels of KYNA in a sustained manner by blocking KMO periph-
erally, and lowers glutamate levels in the brain despite not pene-
trating the blood-brain barrier.866 Cell 145, 863–874, June 10, 2011 ª2011 Elsevier Inc.JM6 Prevents Spatial Memory Loss and Anxiety Deficits
in a Mouse Model of AD
Transgenic (tg) mice that overexpress the human amyloid
precursor protein (hAPP) are a widely used preclinical model of
AD. We next evaluated the effects of JM6 in these APPtg mice,
which express hAPP with two familial AD mutations under
control of the PDGF promoter (‘‘J20’’ mice; Mucke et al.,
2000). These mutations increase the production of the amyloid
b peptide (Ab), which is widely implicated as a disease-causing
agent in AD that forms toxic oligomers and is a component of
amyloid plaques, a neuropathological hallmark of AD.
APPtg mice develop spatial memory deficits starting at
4–5 months of age (Chin et al., 2005). JM6 was administered
to presymptomatic APPtg mice (75 mg/kg/day p.o.) starting
at 2 months of age, and mice were tested behaviorally at
6 months. Vehicle-treated APPtg mice had significant spatial
memory deficits in a Morris water maze assay; however, mutant
mice treated with JM6 showed a significant improvement in
spatial memory (Figure 3A). JM6 had no effect on spatial memory
in WT mice (Figure 3A). Spatial learning was also significantly
impaired in APPtg mice, as described (Chin et al., 2005);
however, JM6 did not influence learning in WT or APPtg mice
(data not shown).
APPtg mice also display deficits in an elevated plus maze
(EPM) assay, a measure of anxiety (Chin et al., 2005). In this
assay, WT mice spend more time in the closed arm of the
maze than in the open arm, whereas APPtg mice spend
increased time in the open arm, consistent with disinhibition.
Vehicle-treated APPtg mice showed an increase in time spent
in the open arm of the maze, but APPtg mice treated with JM6
were not significantly different from WT littermate controls (Fig-
ure 3B). The distance traveled in the open arm was significantly
increased in APPtg mice, and this increase was significantly
attenuated in APPtg mice that received JM6 (Figure 3C). The
total distance traveled in the EPM (open and closed arm) was
also significantly increased in APPtg mice, but this phenotype
was not changed in APPtg mice that received JM6 (Figure 3D).
JM6 Prevents Synaptic Loss in a Mouse Model of AD
Synaptic loss in APPtg mice correlates with spatial memory loss
(Mucke et al., 2000) and may be an important contributor to
pathogenesis in AD patients (Masliah et al., 1989). Consistent
with past studies (Chin et al., 2005), APPtg mice had reduced
levels of synaptophysin in the cortex and hippocampus at
7 months of age (Figures 4A–4D). Synaptic loss was prevented
in APPtg mice treated with JM6. However, JM6 did not have
a significant effect on Ab plaque load, which was increased in
the hippocampus and cortex in APPtg mice (data not shown).
JM6 Increases Brain KYNA Levels in a Mouse Model
of AD
In the serum and CSF of AD patients, tryptophan levels are
reduced and the kynurenine:tryptophan ratio is elevated, coin-
ciding with increased production of proinflammatory cytokines
and chemokines (Gulaj et al., 2010; Heyes et al., 1992a).
APPtg mice had lower brain KYNA levels than WT littermate
controls (Figure 5A). Chronic treatment of APPtg mice with
JM6 (75 mg/kg/day p.o. for 120 days) increased brain and
A B
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Figure 3. JM6 Prevents Spatial Memory
Loss and Anxiety Deficits in a Mouse Model
of AD
(A) JM6 rescues spatial memory deficits in APPtg
mice in the Morris water maze (MWM). Mice were
trained to find a hidden platform in the MWM
using spatial cues. Spatial memory was assessed
24 hr after training by removing the hidden
platform and quantifying how much time mice
spent in the target quadrant where the platform
had been placed previously. APPtg mice that
received JM6 (75 mg/kg/day p.o. for 120 days
starting at day 30) spend significantly more time
in the target quadrant than vehicle-treated
controls. Solid bar, target quadrant; white bar,
average of three other quadrants.
(B) JM6 reduces anxiolytic behavior in APPtg mice
in the elevated plus maze (EPM). APPtg mice are
disinhibited and spend an equal amount of time in
the open and closed arms in the EPM. However,
APPtg mice that receive JM6 spend significantly
more time in the closed arm than in the open arm
and are not significantly different from WT mice.
Values are means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001.
(A and B) For (A) and (B), t tests were used to
calculate differences between target versus other
quadrants and time spent in open versus closed
arm, respectively (n = 8–14 mice per group).
One-way ANOVA was used to calculate differ-
ences among the four experimental groups. JM6
reduces the distance traveled by APPtg mice in
the open arm of the elevated plus maze.
(C and D) APPtg mice that receive JM6 travel significantly less distance in the open arm of the EPM than vehicle-treated controls, but the total travel distance in
both arms of the maze is not different. Values are means ± SEM.
***p < 0.001 (t test, open versus closed arm); **p < 0.01; ***p < 0.001 (one-way ANOVA comparing open arms between groups). n = 8–14 per group. ns, not
significant.plasma levels of KYNA (Figures 5A and 5B). Notably, KMO
activity, 3-HK and QUIN levels in the brains of APPtg mice
treated with JM6, and QUIN levels in plasma were not signifi-
cantly different than in control mice (Figures 5C–5F).
JM6 Increases Survival in a Mouse Model of HD
Wenext evaluated the effects of JM6 in R6/2mice, the best char-
acterized and most widely used genetic model of HD. In these
mice, the first exon of the huntingtin gene (IT-15) with a large
CAG repeat expansion is expressed under the control of the 50
end of human IT-15 (Mangiarini et al., 1996). R6/2 mice reliably
develop progressive neurological phenotypes, including motor
deficits, weight loss, and premature death. These features, along
with the rapid progression of symptoms and the relatively short
life span of the mice, have contributed to their popularity and
utility for preclinical studies.
When administered starting at 4 weeks of age, an early symp-
tomatic stage in these mice, JM6 (7.5 or 25 mg/kg/day p.o.) had
a highly significant, dose-dependent effect on survival (Fig-
ure 6A), as shown by Kaplan-Meier survival analysis. In a sepa-
rate cohort of R6/2 mice that received behavioral enrichment,
which can increase survival of R6/2 mice (Hockly et al., 2002),
JM6 had a similar effect on survival (Figure 6B). JM6 did not influ-
ence body weight but modestly improved performance on anaccelerating rotarod at early stages of disease (data not shown).
Treatment of WT mice with JM6 for 12 months (25 mg/kg/day
p.o.) had no adverse effects on open field behavior, motor
performance, or body weight (data not shown).
JM6 Prevents Synaptic Loss and CNS Inflammation
in a Mouse Model of HD
R6/2 mice are characterized by loss of the presynaptic marker
synaptophysin in the cortex and striatum by 11–15 weeks
(Cepeda et al., 2003; Wacker et al., 2009). JM6 (7.5 or 25 mg/
kg/day p.o.) prevented the loss of synaptophysin in the striatum
(Figures 6C and 6D) and cortex (data not shown) of 12-week-old
R6/2 mice. JM6 also prevented the loss of immunoreactivity of
Fos, a calcium-regulated immediate-early gene product that is
a surrogate marker for neuronal activity and is decreased
(Wacker et al., 2009) in the striatum (Figures 6E and 6F) and
cortex (data not shown) of 12-week-old R6/2mice. These results
suggest that JM6 preserves synapses and also may stabilize
synaptic activity in R6/2 mice. Previous studies in R6/2 mice
and HD brains showed increased staining with an antibody to
the protein Iba1 (Simmons et al., 2007; Wacker et al., 2009),
consistent with microglial activation and/or proliferation. R6/2
mice treated with JM6 had significantly fewer Iba1-positive cells
than vehicle-treated controls (Figures 6G and 6H) and were notCell 145, 863–874, June 10, 2011 ª2011 Elsevier Inc. 867
Figure 4. JM6 Prevents Synaptic Loss in
a Mouse Model of AD
(A–D) JM6 (75mg/kg/day p.o. for 120 days starting
at day 30) prevents synaptic loss in the hippo-
campus and cortex of 7 month-old APPtg mice.
(A and C) Representative images (630X) of serial
sections of the hippocampus (A) and frontal cortex
(C) of WT or APPtg mice immunostained with an
antibody for synaptophysin.
(B and D) Quantification of synaptophysin levels in
the hippocampus (B) and frontal cortex (D) of
APPtg mice treated with JM6. Synaptophysin
levels in APPtg mice treated with JM6 are not
significantly (ns) different than those found in WT
mice.
Values are means ± SEM. **p < 0.01; ***p < 0.001
(one-way ANOVA). n = 5–9 per group.significantly different than WT littermate controls, suggesting
that microglial activation was prevented in the brains of these
mice.
R6/2 mice also display neuronal inclusion bodies (Scherzinger
et al., 1997), a pathological hallmark of HD and other polyglut-
amine diseases (DiFiglia et al., 1997). Immunohistochemical
experiments on brain sections from the frontoparietal cortex of
R6/2 mice treated chronically with JM6 indicated that JM6 did
not influence inclusion body size (data not shown) or abundance
(Figures 6I and 6J).
Consistent with acute studies in rats (Figures 2C and 2D), Ro
61-8048 released from JM6 accumulated in plasma from
chronically treated R6/2 mice at a concentration of 280 nM,
i.e., > 8-fold higher than its IC50 for KMO (37 nM), but could
not be detected in brain or muscle homogenates (data not
shown).
DISCUSSION
This study shows that prolonged oral administration of JM6,
a novel prodrug inhibitor of KMO, ameliorates neurodegenera-
tion in well-established genetic mouse models of AD and HD.
Inhibition of KMO by JM6-derived Ro 61-8048 in the blood pre-
vented behavioral deficits, synaptic loss, and other markers of
neurodegeneration, even though neither the prodrug nor its
metabolite, which directly inhibits KMO, crosses the blood-brain
barrier into the CNS. Our findings demonstrate that peripheral
inhibition of KMO raises brain levels of the neuroprotective
KP metabolite KYNA while decreasing glutamate release in
a sustained manner. Because KMO is expressed at high levels
in peripheral immune cells such as macrophages (Heyes
et al., 1992b), our findings suggest that KMO and its effects on
tryptophan metabolism in the KP constitute a critical mediator868 Cell 145, 863–874, June 10, 2011 ª2011 Elsevier Inc.between the peripheral immune system
and excitotoxic processes in the CNS.
Consistent with a neuroprotective role
for KYNA, prolonged peripheral adminis-
tration of relatively large doses of the
KMO substrate kynurenine (which leads
to increased brain KYNA) rescues behav-ioral and neuropathological deficits in acute models of neurode-
generation (Carrillo-Mora et al., 2010; Silva-Adaya et al., 2010).
However, peripheral inhibition of KMO using the prodrug meth-
odology described here may be a safer and more attractive ther-
apeutic approach because it involves modest and sustained
elevations in brain KYNA levels without increasing 3-HK and
QUIN levels in the blood and brain. This will avoid potential
adverse consequences both within the brain and on peripheral
immune system function.
Our findings suggest that JM6 is neuroprotective by raising
CNS levels of KYNA and by decreasing glutamate levels and
thus excitotoxicity mediated by glutamate receptors (Figure 7).
Interestingly, other studies implicate deficient glutamate uptake
in HD (Lie´vens et al., 2001) and AD (Masliah et al., 1996), and
increased expression of the glutamate transporter GLT1 is neu-
roprotective in amousemodel of HD (Miller et al., 2008). Notably,
because JM6 does not increase CNS KYNA levels sufficiently
to block glutamate receptors directly, it is likely that decreased
extracellular glutamate observed after JM6 treatment
is caused secondarily following KYNA antagonism of a7 nicotinic
acetylcholine receptors (Hilmas et al., 2001). Consistent with this
scenario, deletion of the a7 nicotinic acetylcholine receptor gene
improves cognitive deficits and synaptic pathology in a mouse
model of AD (Dziewczapolski et al., 2009).
Neuroprotection by KYNAmay also be due, in part, to its ability
to regulate innate and adaptive immune responses (Romani
et al., 2008). For example, KYNA is an agonist of GPR35, an
orphan G protein-coupled receptor that reduces production of
the proinflammatory cytokine TNF-a (Wang et al., 2006), which
is found at abnormally high levels in patients with HD (Bjo¨rkqvist
et al., 2008) and AD (Fillit et al., 1991). Inhibition of TNF-a
signaling is neuroprotective in mouse models of AD (Yamamoto
et al., 2007). Although we did not directly measure levels of
A B 
C D
E F
Figure 5. JM6 Increases Brain KYNA Levels
in a Mouse Model of AD
(A) Compared toWTmice, cortical KYNA levels are
significantly reduced in APPtgmice, and the deficit
is normalized by JM6 treatment (75 mg/kg/day
p.o. for 120 days starting at day 30).
(B) Plasma KYNAmeasurements in the same three
groups show a similar pattern as in the brain.
(C–F) No group differences are seen in cortical
KMO activity (C), 3-HK levels (D), and QUIN levels
(E), as well as in plasma QUIN levels (F).
Values are means ± SEM. n = 5–15 per group,
except APPtg controls in (B), for which n = 3.
*p < 0.05; **p < 0.01 (t test). ns, not significant.TNF-a and other proinflammatory cytokines in our studies, treat-
ment of R6/2 mice with JM6 normalized levels of a protein
marker for microglia, suggesting a decrease in the inflammatory
environment in the CNS of these mice. Future studies will be
required to elucidate fully how JM6 and KMO modulate the
immune system in mouse models of neurodegeneration.
A recent complementary study provides compelling genetic
and pharmacological evidence that KMO modulates neurode-
generation in a fruit fly model of HD (Campesan et al., 2011)
and that an increased KYNA:3-HK ratio provides neuroprotec-
tion. Genetic dissection in the flies indicated that KP enzymes
other than KMO might also be attractive therapeutic targets
for HD and other neurodegenerative diseases. Notably, the
experiments described by Campesan et al. and in our current
study stemmed, in part, from the identification of KMO in a yeast
genetic screen designed to isolate suppressors of mutant
huntingtin toxicity (Giorgini et al., 2005). Interestingly, geneticCell 145, 863–8or pharmacological inhibition of KMO
suppressed mutant huntingtin toxicity
in yeast, despite the absence of genes
that encode neurotransmitter receptors
and immune signaling molecules in the
yeast genome. However, mutant hunting-
tin toxicity in yeast was tightly correlated
to increased levels of 3-HK, QUIN, and
reactive oxygen species (Giorgini et al.,
2005). As KMO is an outer mitochondrial
membrane protein, these results sug-
gest that KMO and KP metabolites
may also influence neurodegenerative
processes by modulating mitochondrial
function. Thus, our results provide addi-
tional evidence that genetic screens
in model organisms can successfully
identify disease-modifying pathways
that are conserved in lower and higher
eukaryotes.
In summary, because neurodegenera-
tive disorders such as AD and HD are
characterized by increased levels of toxic
KP metabolites and decreased levels of
KYNA, a rational strategy for treating
these disordersmay be to normalize brainlevels of KYNA by inhibiting KMO in blood cells. KYNA may be
beneficial in these diseases due to its ability to modulate neuro-
transmission, immune cell function, and mitochondrial function
in a manner that contributes to neuroprotection.
EXPERIMENTAL PROCEDURES
Synthesis of 2-(3,4-Dimethoxybenzenesulfonylamino)-4-
(3-Nitrophenyl)-5-(Piperidin-1-yl)Methylthiazole
To a stirred solution of Ro 61-8048 (structure in Figure 2) in ethanol was added
10 molar equivalents of aqueous formaldehyde (37 WT %) and an equimolar
amount of the amine. After 0.5 hr, the precipitated solid was collected by
filtration, washed successively with water and ethanol, and dried in vacuo to
generate JM6. JM6 (structure in Figure 2) was obtained in 88% yield and
had a melting point of 193C –194C. 1H NMR (DMSO d6) d 1.39 (bs, 2H),
1.52 (bs, 4H), 2.45 (bs, 4H), 3.55 (bs, 2H), 3.79 (s, 3H), 3.83 (s, 3H), 7.07
(d, 1H, J = 8.4 Hz), 7.30 (d, 1H, J = 2.0 Hz), 7.39 (dd, 1H, J = 8.4, 2.0 Hz),
7.74 (t, 1H,), 7.93 (d, 1H, J = 8.0 Hz), 8.25 (dd, 1H, J = 8.4, 1.6 Hz), 8.43
(s, 1H), 12.41 (bs, 1H); MS-ESI m/z 519 (MH)+.74, June 10, 2011 ª2011 Elsevier Inc. 869
Figure 6. JM6 Prevents Neurodegeneration
in a Mouse Model of HD
(A) Kaplan-Meier survival analysis shows that
chronic JM6 administration (7.5 or 25 mg/kg/day
p.o., starting at 4 weeks of age) increases survival
in R6/2 mice in the absence of behavioral enrich-
ment. Log rank; p = 0.017; n = 8–13 per group.
(B) Kaplan-Meier survival analysis shows that
chronic JM6 administration (25 mg/kg/day p.o.
starting at 4 weeks of age) increases survival in an
independent cohort of R6/2 that received behav-
ioral enrichment. Log rank; p = 0.005; n = 14–15
per group.
(C and D) JM6 (7.5 or 25 mg/kg/day p.o., starting
at 4 weeks of age) prevents synaptic loss in R6/2
mice. (C) Representative images (6303) of serial
sections of striatum from WT or R6/2 mice
immunostained with an antibody for synaptophy-
sin. (D) Quantification of synaptophysin levels in
R6/2 mice treated with JM6.
(E and F) JM6 (7.5 or 25mg/kg/day p.o., starting at
4 weeks of age) prevents the loss of Fos, a marker
for neuronal activity, in R6/2 mice. (E) Represen-
tative images (4403) of serial sections of the
striatum from WT or R6/2 mice immunostained
with an antibody for Fos. (F) Quantification of Fos
levels in R6/2 mice treated with JM6.
(G and H) JM6 (7.5 or 25 mg/kg/day p.o., starting
at 4 weeks of age) decreases CNS inflammation in
R6/2 mice. (G) Representative images (4403) of
serial sections of the striatum from WT or R6/2
mice immunostained with an antibody against
Iba1 that labels microglia. (H) Iba1 levels in R6/2
mice treated with JM6 (7.5 or 25 mg/kg/day p.o.,
starting at 4 weeks of age). Levels of synapto-
physin, Fos, and Iba1 in R6/2 mice treated with
JM6 are not significantly different than those inWT
mice.
(I) Brain sections from the cortex of 97- to 139-
day-old R6/2 mice that received JM6 (25 mg/kg/
day p.o., starting at 4 weeks of age) were immu-
nostained with an anti-huntingtin antibody (EM48).
Inclusion bodies increase in size and abundance
between 97 and 139 days of age.
(J) In the same animals, JM6 does not significantly
decrease the abundance of inclusion bodies, as
determined by quantification of EM48 im-
munostaining.
Values are means ± SEM. **p < 0.01; ***p < 0.001
(one-way ANOVA). n = 5–13 per group. ns, not
significant.Animals and Behavioral Testing
All animals were housed and handled in accordance with the National Insti-
tutes of Health ‘‘Guide for the Care and Use of Laboratory Animals.’’ All studies
were approved by the Institutional Animal Care and Use Committee of the
University of California, San Francisco (mice) or the University of Maryland,
Baltimore (rats). All animals were housed in pathogen-free barrier facilities
on a 12 hr light/dark cycle. Male and female R6/2 mice used in the study
with 113 ± 0.5 CAG repeats were generated from the sixth generation back-
cross of male R6/2 breeders to C57BL/6 females. CAG sizing was performed
by PCR amplification with a labeled primer using an ABI3730with genemapper
software (Laragen, Culver City, CA). APPtg mice were maintained on a C57BL/
6 background (Harris et al., 2010). Mice were genotyped using DNA from tail
snips and group housed with access to water and food ad libitum. Behavioral
testing occurred between 8 AM and 5 PM during the light cycle, except where870 Cell 145, 863–874, June 10, 2011 ª2011 Elsevier Inc.noted. Experimenters were blind to mouse genotype and treatment during
testing. Survival in R6/2 mice was evaluated as the time when the animals
either died spontaneously or had lost more than 20% of their maximal weight.
APPtg mice were tested using the Morris water maze and EPM at 7 months of
age, as described (Harris et al., 2010).
Acute and Chronic Administration of JM6
For all acute studies, JM6 was administered as a sonicated suspension in
0.1% Tween-80 in water by oral gavage. For chronic administration, JM6
was weighed and mixed with powdered chow (Lab Diet, Richmond, IN) in
a blender. A single glass feeding jar (Dyets, Bethlehem, PA) that contained
powdered chow (with and without treatment) was placed in each cage and
refilled as necessary. Feeders were monitored each day, and body weight
was determined twice per week.
Figure 7. A Model Illustrating the Mechanism by Which KMO Inhibition in Blood Cells Leads to Elevated Brain KYNA Levels and Neuro-
protection
In neurodegenerative diseases like HD and AD, increased levels of the toxic kynurenine pathway metabolites 3-HK and QUIN and decreased levels of the
neuroprotective pathwaymetabolite KYNAmight contribute to increased glutamatergic neurotransmission, elevation of intracellular calcium levels, mitochondrial
dysfunction, and ultimately neuronal dysfunction and cell death (inset labeled ‘‘Disease/Excitotoxicity’’). We hypothesize that the biotransformation of JM6 to Ro
61-8048 in the gut (not shown) results in KMO inhibition in peripheral monocytes, causing the accumulation of both kynurenine (KYN) and KYNA in blood. Unlike
KYNA, KYN is then actively transported into the brain, where it is rapidly converted by astrocytes to KYNA. KYNA released from astrocytes mediates neuro-
protection, at least in part, by decreasing glutamate levels via antagonism of presynaptic a7 nicotinic acetylcholine receptors (inset labeled ‘‘Neuroprotection with
JM6’’). However, at high local concentrations, KYNA might also directly block glutamate receptors to reduce excitotoxicity. Neuroprotection by JM6 might also
involve a decrease in inflammation and modulation of mitochondrial function (not shown).In Vivo Brain Microdialysis and Blood Sample Collection
Male Sprague-Dawley rats (280–350 g) were anesthetized with chloral hydrate
(360 mg/kg i.p.) and placed in a David Kopf stereotaxic frame. A guide
cannula (outer diameter 0.65 mm) was positioned over the striatum (AP,
1 mm anterior to bregma; L, 2.5 mm from midline; V, 3.5 mm below the
dura) and secured to the skull with acrylic dental cement and anchor screws.
On the next day, a microdialysis probe (CMA/10, membrane length: 2–4 mm,
Carnegie Medicin, Stockholm, Sweden) was inserted through the guide
cannula and connected to a microperfusion pump set to a speed of 1 ml/
min. The freely moving animals were perfused with Ringer solution containing
(in mM): NaCl, 144; KCl, 4.8; MgSO4, 1.2; CaCl2, 1.7; pH 6.7. Where indicated,
ESBA (kindly provided by R. Pellicciari, Univ. Perugia, Italy) was applied by
reverse dialysis for 2 hr. Subsequently, perfusion with Ringer solution
continued. Microdialysis samples were collected every 30 or 60 min for the
duration of the experiment. To obtain blood samples, rats received a jugular
vein catheter (polyethylene tubing, 0.58 mm inner diameter) during anesthesia
for the guide cannula implantation described above. The catheter was
kept patent by filling it with a 5 mM EDTA solution to prevent coagulation.
On the next day, blood (500 ml) was withdrawn hourly during ongoing
microdialysis.Essentially identical methods were used to obtain brain microdialysis and
blood samples, respectively, for the measurement of JM6 and Ro 61-8048
in separate rats.
Analysis of KP Metabolites, Glutamate, JM6, and Ro 61-8048
Tissues were sonicated (1:5, wt/vol) in ultrapure water. Twenty five ml of 6%
perchloric acid were added to 100 ml of the homogenate, and the suspension
was thoroughly mixed and centrifuged (16,0003 g for 15min). Twenty ml of the
supernatant were subjected to HPLC analysis. KYNA was determined fluori-
metrically (excitation, 344 nm; emission, 398 nm), and 3-HK was measured
electrochemically (oxidation potential: +0.5 V) (modified from Guidetti et al.,
2006).
For the determination of serum KYNA levels (Figure 2F), venous blood was
allowed to clot (15 min) and was then centrifuged (microfuge). For KYNA
measurement in plasma (Figure 5B), blood was collected in EDTA-containing
tubes and centrifuged (microfuge). Both preparations were diluted (1:10, vol/
vol) and deproteinated (25 ml of 6% perchlorate added to 100 ml; see above),
and 20 ml of the respective supernatant were subjected to HPLC analysis.
KYNA and glutamate levels in microdialysate samples were determined
as described previously (Rassoulpour et al., 2005). QUIN was quantified byCell 145, 863–874, June 10, 2011 ª2011 Elsevier Inc. 871
GC/MS in the same tissue or plasma used for the determination of KYNA.
Analyses were performed on a 7890A GC coupled to a 7000 MS/MS (Agilent
Technologies, Santa Clara, CA), using an adaptation of the method described
by Eckstein et al. (2008). The concentrations of JM6 and Ro 61-8048 were
determined by LC/MS in appropriate microdialysate, plasma, and tissue
samples.
Measurement of KMO Activity
Brain tissue was homogenized 1:5 (wt/vol) in ultrapure water and further
diluted 1:5 (vol/vol) in 100 mM Tris-HCl buffer (pH 8.1) containing 10 mM KCl
and 1 mM EDTA. Eighty ml of the tissue preparation were incubated for
40 min at 37C in a solution containing 1 mM NADPH, 3 mM glucose-6-phos-
phate, 1 U/ml glucose-6 phosphate dehydrogenase, 100 mM kynurenine,
10 mM KCl, and 1 mM EDTA in a total volume of 200 ml. The reaction was
stopped by the addition of 50 ml of 6% perchloric acid. Blanks were obtained
by adding the specific enzyme inhibitor Ro 61-8048 (100 mM) in the incubation
solution. After centrifugation (16,000 3 g, 15 min), 20 ml of the supernatant
were applied to HPLC to measure 3-HK (see above).
Neuropathological Analyses
The right hemibrain was immersion-fixed in 4% paraformaldehyde in phos-
phate-buffered saline (PBS) (pH 7.4) and serially sectioned at 40 mm with
a microtome (Vibratome, Leica, Deerfield, IL) for neuropathological analysis,
as described (Harris et al., 2010). To investigate the effects of JM6 on levels
of mutant huntingtin immunoreactivity in R6/2 mutant mice, the sections
were immunolabeled overnight with a rabbit polyclonal antibody (EM48,
Chemicon) against a glutathione S transferase fusion protein containing the
first 256 amino acids of huntingtin lacking the polyQ and polyproline stretches.
Sections were washed in PBS and placed in biotinylated secondary antibody
(1:100) (Vector Laboratories, Burlingame, CA) for 2 hr. Sections were placed in
20% diaminobenzidene (DAB) (Vector Laboratories), mounted, dried, and
coverslipped with Entillin (Fisher). Three immunostained sections per mouse
were imaged with an Olympus digital microscope. A total of 10 digital images
per section and region of interest were analyzed with Image-Pro Plus to
determine the optical density per field and the mean diameter and number
of intranuclear inclusions. Individual values were averaged and expressed
as mean value. To investigate the effects of JM6 on microglial activation,
microtome sections fromR6/2 mice were immunostained with a mousemono-
clonal antibody against Iba-1 (microglial cell marker, 1:1000, DakoCytomation,
Carpinteria, CA) followed by biotinylated secondary antibody, avidin coupled
to horseradish peroxidase, and reacted with DAB, as described (Harris
et al., 2010). Sectionswere analyzed, and the numbers of Iba-1-positivemicro-
glia were averaged and expressed as total number per 0.1 mm3. To determine
the number of microglia per unit area, 10 digital images per field were obtained
and analyzed with Image-Pro Plus. From each case, at least three blind-coded
random sections were analyzed, and the results were averaged and expressed
as mean value. To investigate the effect of JM6 on plaque load in APPtg mice,
microtome sections were immunostained with a biotinylated monoclonal
mouse antibody 3D6 (Elan Pharmaceuticals) against amyloid b peptide
followed by avidin coupled to horseradish peroxidase and reacted with DAB
as described (Harris et al., 2010). Images of hippocampus and cortex were
obtained with a Leica DM5000 B microscope, and the percent area covered
by 3D6 immunoreactive material was analyzed with Image J, version 1.43u.
Two sections were analyzed per mouse.
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